Marina Aims to Raise $5.1M in Public Offering | GenomeWeb

Marina Biotech said this week that it has priced an underwritten public offering of 6.375 million units of stock and warrants at $0.80 each, for total gross proceeds of $5.1 million.

Each unit, Marina said, consists of one share of common stock and 0.1746 of a warrant to buy one share of common stock. The warrants are exercisable immediately and have a seven-year term.

The offering is expected to close mid-February, the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.